This content is from: United States

Patent paradox: using global strategy to protect country-specific assets

The globalisation of the biopharma industry has made it increasingly essential for companies to consider parallel patent proceedings across multiple countries, as April Abele Isaacson of Kilpatrick Townsend explains

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial